{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:51:59Z","timestamp":1789692719407,"version":"4.0.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,15]]},"DOI":"10.1093\/infdis\/jit164","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T23:12:27Z","timestamp":1366326747000},"page":"351-361","source":"Crossref","is-referenced-by-count":56,"title":["Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients"],"prefix":"10.1093","volume":"208","author":[{"given":"Lucy","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Livermore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Gregson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Felton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Perfect","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,4,18]]},"reference":[{"key":"key\n\t\t\t\t20170511121927_JIT164C1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"Aids"},{"key":"key\n\t\t\t\t20170511121927_JIT164C2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511121927_JIT164C3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tim.2010.02.004","article-title":"Therapy for fungal diseases: opportunities and priorities","volume":"18","author":"Denning","year":"2010","journal-title":"Trends Microbiol"},{"key":"key\n\t\t\t\t20170511121927_JIT164C4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety","volume":"51","author":"Hamill","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511121927_JIT164C5","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511121927_JIT164C6","first-page":"1721","article-title":"Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis","volume":"49","author":"Sun","year":"2009"},{"key":"key\n\t\t\t\t20170511121927_JIT164C7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/AAC.50.1.113-120.2006","article-title":"Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis","volume":"50","author":"Schwarz","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511121927_JIT164C8","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Clinical Laboratory Sciences Institute","year":"2008","edition":"3rd ed"},{"key":"key\n\t\t\t\t20170511121927_JIT164C9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/432069","article-title":"Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis","volume":"192","author":"Hope","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121927_JIT164C10","first-page":"389","article-title":"An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK\/PD) models","author":"Leary","year":"2001"},{"key":"key\n\t\t\t\t20170511121927_JIT164C11","volume-title":"ADAPT 5 user's guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"D'Argenio","year":"2009"},{"key":"key\n\t\t\t\t20170511121927_JIT164C12","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01601-08","article-title":"Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect","volume":"53","author":"Warn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511121927_JIT164C13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270003253624","article-title":"Model appropriateness and population pharmacokinetic modeling","volume":"43","author":"Ette","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170511121927_JIT164C14","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00933-12","article-title":"Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511121927_JIT164C15","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1128\/IAI.00624-06","article-title":"Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans","volume":"74","author":"Petzold","year":"2006","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170511121927_JIT164C16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511121927_JIT164C17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511121927_JIT164C18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1128\/AAC.01188-06","article-title":"Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis","volume":"51","author":"Brouwer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511121927_JIT164C19","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/208\/2\/351\/16866758\/jit164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T09:35:09Z","timestamp":1503480909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jit164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,4,18]]},"published-print":{"date-parts":[[2013,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jit164","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718001671.793479268","asserted-by":"object"}]},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"value":"1537-6613","type":"electronic"},{"value":"0022-1899","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,18]]}}}